Cyclotriazadisulfonamide (CADA) is a selective, CD4-targeted HIV inhibitor and Sec61 inhibitor that downregulates CD4 T-cell receptors and restricts CD4 translocation, thereby limiting HIV binding and entry. It exhibits activity against multiple HIV strains.

Cyclotriazadisulfonamide is a selective inhibitor of the Sec61 translocon. A proteomics study targeting T cells revealed that this compound has only five substrate targets: huCD4, SORT, CD137, DNAJC3, PTK7, and ERLEC1, with IC50 values ranging from 0.2 to 2 μM [3].
Cyclotriazadisulfonamide (CADA) significantly reduces the expression level of cell surface CD4 protein while showing no effect on the expression of any other tested cellular receptors [1].
In MO-DC cells, the EC50 of CADA for downregulating CD4 protein is 0.4 μg/mL. Treatment of MO-DC cells with 10 μg/mL CADA resulted in an 83% downregulation of cell surface CD4 protein expression, an effect similar to that observed in CADA-treated CD4+ T cells [1].
CADA protects MT-4 cells from infection by HIV-1 and SIV, with corresponding EC50 values of 0.7 μg/mL and 1.2 μg/mL, respectively [1].